Arialys was featured in PharmaVoice's Biotech Spotlight, a series featuring companies creating breakthrough technologies and products.

In this article, Arialys' CEO Peter Flynn shares more about the vision of the company, why it matters, the terrifying and rapid symptoms of anti-NMDA receptor encephalitis (ANRE) and how ART-5803, our lead therapeutic candidate to treat autoimmune psychosis is “elegantly simple.”

Read the article here.

‍